Richard A. Meier Sells 3,000 Shares of BioMarin Pharmaceutical Inc. (BMRN) Stock
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Richard A. Meier sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $99.24, for a total value of $297,720.00. Following the sale, the director now directly owns 81,610 shares in the company, valued at approximately $8,098,976.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
NASDAQ BMRN opened at $99.77 on Thursday. BioMarin Pharmaceutical Inc. has a 1 year low of $75.81 and a 1 year high of $106.20. The company has a current ratio of 2.83, a quick ratio of 2.24 and a debt-to-equity ratio of 0.28.
BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.03). The company had revenue of $372.80 million during the quarter, compared to the consensus estimate of $359.25 million. BioMarin Pharmaceutical had a negative net margin of 8.68% and a negative return on equity of 3.00%. BioMarin Pharmaceutical’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.21) EPS. equities analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.24 earnings per share for the current fiscal year.
BMRN has been the topic of several recent analyst reports. Wedbush boosted their target price on BioMarin Pharmaceutical from $112.00 to $115.00 and gave the stock an “outperform” rating in a report on Friday, May 25th. Morgan Stanley boosted their target price on BioMarin Pharmaceutical from $113.00 to $115.00 and gave the stock an “overweight” rating in a report on Friday, August 3rd. TheStreet raised BioMarin Pharmaceutical from a “d+” rating to a “c-” rating in a report on Friday, August 17th. Credit Suisse Group boosted their target price on BioMarin Pharmaceutical from $116.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, May 25th. Finally, Zacks Investment Research cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Tuesday, June 26th. One research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $116.28.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.
Read More: What is a Fiduciary?
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.